XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

XTX Topco Ltd grew its stake in 10x Genomics, Inc. (NASDAQ:TXG) by 241.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 45,008 shares of the company’s stock after purchasing an additional 31,844 shares during the quarter. XTX Topco Ltd’s holdings in 10x Genomics were worth $1,016,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of 10x Genomics by 2.7% in the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after purchasing an additional 357,470 shares during the period. ARK Investment Management LLC raised its stake in 10x Genomics by 15.4% during the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after buying an additional 1,436,582 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in 10x Genomics by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,373,212 shares of the company’s stock worth $143,907,000 after buying an additional 230,145 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in 10x Genomics by 69.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company’s stock worth $119,483,000 after buying an additional 2,521,289 shares during the period. Finally, State Street Corp raised its stake in 10x Genomics by 7.1% during the 3rd quarter. State Street Corp now owns 1,750,643 shares of the company’s stock worth $39,530,000 after buying an additional 116,534 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the topic of several research analyst reports. Stephens reaffirmed an “overweight” rating and set a $30.00 price objective on shares of 10x Genomics in a research note on Thursday, October 10th. The Goldman Sachs Group dropped their price objective on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research note on Wednesday, October 30th. Canaccord Genuity Group dropped their price objective on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, October 10th. JPMorgan Chase & Co. lowered their target price on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. Finally, UBS Group lowered their target price on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.19.

10x Genomics Price Performance

NASDAQ:TXG opened at $16.15 on Wednesday. The company has a market cap of $1.96 billion, a P/E ratio of -10.56 and a beta of 1.84. The firm’s fifty day moving average price is $16.12 and its two-hundred day moving average price is $19.15. 10x Genomics, Inc. has a one year low of $12.95 and a one year high of $57.90.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04. The company had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.51) earnings per share. As a group, equities research analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.